OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), the AIM-listed life sciences company developing microbiome-modulating ingredients, has announced an exclusive distribution agreement with CK Ingredients Inc. for its appetite-reducing SlimBiome ingredient across North America, covering both Canada and the United States. The deal, entered into through OptiBiotix's wholly owned subsidiary OptiBiotix Limited, hands CK Ingredients responsibility for sales, logistics, warehousing, and customer management across the region. The board states it expects the arrangement to reduce operating costs and eliminate the need for OptiBiotix to hold its own stock in North America, which investors may regard as a meaningful operational efficiency.
Key Points
- OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF)
- Exclusive distribution agreement signed with CK Ingredients Inc. for SlimBiome in Canada and the USA
- Exclusivity is conditional on CK meeting annual minimum order quantities; OptiBiotix retains the option to convert to non-exclusive if minimums are not met
- Investors should watch for updates on CK's progress in building the North American customer pipeline and any order volume disclosures
CK Ingredients to Acquire Existing SlimBiome US Stock and Manage Hydroxycut Account
Under the terms of the agreement, CK Ingredients will acquire OptiBiotix's existing SlimBiome stock held in the United States and take over responsibility for import, logistics, and warehousing across North America. CK will also manage existing customer accounts — including Hydroxycut, which is named in the announcement — and assume responsibility for pipeline projects. Incorporated in Ontario, Canada in 1994, CK Ingredients describes itself as a professional sales, marketing, and distribution business focused on trademarked, evidence-backed functional raw materials, distinguishing itself from suppliers of generic ingredient portfolios.
SlimBiome Positioned Against Growing GLP-1 Category Interest in North American Market
Michael Chenyak, President of CK Ingredients, is quoted in the announcement stating that interest in the GLP-1 category is "burgeoning" and describing SlimBiome as a "science-backed solution" for consumers seeking to manage weight and metabolic function. He anticipates "very robust demand" from North American supplement and functional food brands. OptiBiotix CEO Stephen O'Hara noted that CK's focus on high-value, science-based ingredients makes it a distinctive partner for SlimBiome, which requires a technical and scientific sales approach. The annual minimum order quantity structure provides OptiBiotix with a contractual safeguard on exclusivity.
Operational Cost Reduction Expected as OptiBiotix Exits Direct North American Stockholding
The board of OptiBiotix has stated it expects the agreement to reduce operating costs by removing the requirement for the company to maintain its own stock in North America. This operational rationale is a central element of the disclosure, suggesting the deal is structured to improve capital efficiency as well as expand commercial reach. OptiBiotix operates a broader portfolio of microbiome-based products including WellBiome, SweetBiotix, and Microbiome Modulators, alongside interests in SkinBioTherapeutics plc (SBTX) and ProBiotix Health plc (PBX), providing context for the strategic importance of optimising the core ingredient business.




Please wait processing your request...